5th International Chronic GvHD Symposium
Zagreb, Croatia, April 15-16th 2021
Virtual congress


ONLINE  suport will open an hour before the beginning of the sessions and close after the sessions.

Official languages is English. Simultaneous translation will not be provided.

Certificates of attendance will be issued to all congress participants in accordance with the rules of professional chambers.



Dear friends and colleagues,

It is our great pleasure to invite you to the 5th International Chronic Graft-versus-Host Disease Symposium that will be organized in Zagreb, Croatia, from April 15-16th, 2021. Depending on COVID-19 epidemiology situation, the symposium will be organized mostly or completely as a virtual meeting.

Approximately 50% of transplanted patients will develop chronic graft-versus-host disease (cGvHD) which can last for many years causing severe medical, social and quality of life problems. However, more than ever before, the tools are at our hands to address cGvHD conclusively and improve outcomes of patients after alloHSCT. Such progress in a relatively rare and complex disease can be achieved only by the assertive interdisciplinary and multicenter international collaboration.

This 5th International cGvHD Symposium in Zagreb brings together prominent experts in the field of cGvHD from Europe, United States of America, and Canada. Symposium will be divided in several sections: 1) Highlights from the newest 2020 NIH cGvHD consensus project, 2) Chronic GvHD progress review 3) Interactive cases for Hematology Residents and young Hematologists, and 4) Future projects proposals.

The goal of the meeting is to disseminate the most current knowledge regarding cGvHD, and to provide a venue for networking and establishing contacts for our future collaborations in addressing cGvHD. This event is expected to create a critical mass of investigators and colleagues who will carry this field in the near future. It is dedicated to physicians and scientists who are engaged in management, research, and advancing care of alloHSCT patients.

It is with delight that we invite you to attend and be part of this unique advanced continuing education experience.

With warm regards,


Dražen Pulanić (Zagreb, Croatia)

Steven Z. Pavletic (Bethesda, MD, USA)

Daniel Wolff (Regensburg, Germany)

Kirk Schultz (Vancouver, Canada)

Radovan Vrhovac (Zagreb, Croatia)



Croatian Cooperative Group for Hematological Diseases KROHEM



Dražen Pulanić (Zagreb, Croatia)
Steven Z. Pavletic (Bethesda, MD, USA)
Daniel Wolff (Regensburg, Germany)
Kirk Schultz (Vancouver, Canada)
Radovan Vrhovac (Zagreb, Croatia)




THURSDAY, April 15th, 2021

Drazen Pulanić (Croatia), Steven Z. Pavletić (USA), Daniel Wolff (Germany), Kirk Schultz (Canada), Radovan Vrhovac (Croatia)

17:10-17:20  Steven Z. Pavletić (USA): Rationale for 3rd 2020 NIH cGvHD consensus

17:20-20:00 PART I: Highlights from the newest 2020 NIH cGvHD consensus project
Chairs: S.Z. Pavletić (USA), D. Wolff (Germany), K. Schultz (Canada)

17:20-18:00 Working Group 1: Etiology and Prevention of cGvHD (moderators K. Schultz (Canada), R. Serventi Seiwerth (Croatia))

17:20-17:35  K. Williams (USA): Etiology of cGvHD
17:35-17:50  S. Sarantopoulos (USA): Prevention of cGvHD
17:50-18:00  Discussion

18:00-18:40 Working Group 2: Diagnosis and Pre-emptive treatment of cGvHD (moderators A. Lawitschka (Austria), L. Desnica (Croatia))

18:00-18:15  H. Schoemans (Belgium): Early diagnosis of cGvHD
18:15-18:30  F. Ayuk (Germany): Pre-emptive treatment of cGvHD
18:30-18:40  Discussion

Coffee break 18:40-18:50

18:50-19:30 Working Group 3: Treatment of Established cGvHD (moderators J. Halter (Switzerland), D. Pulanić (Croatia))

18:50-19:05  H. Greinix (Austria): Upfront therapy of cGVHD – current and future options
19:05-19:20  A. Olivieri (Italy): Salvage therapy of cGVHD – current and future options
19:20-19:30  Discussion

19:30-20:30 Working Group 4: Highly morbid forms of cGvHD (moderators R. Zeiser (Germany), R. Vrhovac (Croatia))

19:30-19:40: D. Wolff (Germany): Eye, GI, and autoimmune manifestations in cGvHD
19:40-19:50: A. Rambi G. Cardones (USA): Skin cGVHD
19:50-20:00  A. Bergeron (France): Lung cGvHD
20:00-20:10  O. Penack (Germany): Endothelial dysfunction in cGvHD
20:10-20:20  E. Bilić (Croatia): CNS/peripheral neuropathy in cGvHD
20:20-20:30  Discussion


FRIDAY, April 16th, 2021


Mallinckrodt 45 min (gold sponsor)
MSD 45 (gold sponsor)
Takeda 30 (silver sponsor)
Pfizer 15 (bronze sponsor)

10:30-10:45 Coffee break

10:45-12:15 PART II: Chronic GvHD progress review (moderators H. Greinix (Austria), Z. Perić (Croatia))

12:15-13:30 LUNCH BREAK

13:30-14:45 PART III: CASE-BASED EDUCATIONAL TOPICS for Hematology Fellows and young Hematologists
(moderators E. Bilić (Croatia), D. Wolff (Germany), J. Halter (Switzerland), N. Duraković (Croatia))

14:45-15:00 COFFE BREAK


15:00-15:30 Patients advocacy – what matters from the patients’ view?
M. Cowden (USA) and H. Schoemans (Belgium)

15:30-17:00 PART V: FUTURE PROJECTS (panelists: H. Greinix (Austria), D. Wolff (Germany), H. Schoemans (Belgium), M. Grce (Croatia), D. Pulanić (Croatia), A. Olivieri (Italy), A. Lawitschka (Austria), R. Duarte (Spain), R. Vrhovac (Croatia), M. Mohty (France), S.Z. Pavletić (USA), K. Schultz (Canada), Anne Dickinson (USA))

15:30-15:45  B. Blazar (USA): Next steps in biology guided treatment of cGvHD
15:45-15:50  Discussion
15:50-16:05  K. Schultz (Canada): Global aspects of cGvHD
16:05-16:10  Discussion
16:10-16:25  Z. DeFilipp (USA): Novel structure for trials design
16:25-16:30  Discussion
16:30-16:45  M. Inngjerdingen (Norway): European grant options for cGvHD
16:45-16:50  Discussion

16:50-17:00  Discussion

Drazen Pulanić (Croatia), Steven Z. Pavletić (USA), Daniel Wolff (Germany), Kirk Schultz (Canada), Radovan Vrhovac (Croatia)






F. Ayuk (Germany)
A. Bergeron (France)
E. Bilić (Croatia)
B. Blazar (USA)
M. Cowden (USA)
Z. DeFilipp (USA)
L. Desnica (Croatia)
A. Dickinson (USA)
R. Duarte (Spain)
N .Duraković (Croatia)
M. Grce (Croatia)
H. Greinix (Austria)
J. Halter (Switzerland)
M.Inngjerdingen (Norway)
A. Lawitschka (Austria)
M. Mohty (France)
A. Olivieri (Italy)
S. Z. Pavletić (USA)
O. Penack (Germany)
Z. Perić (Croatia)
D. Pulanić (Croatia)
A. Rambi G. Cardones
S. Sarantopoulos (USA)
H. Schoemans (Belgium)
K. Schultz (Canada)
R. Serventi Seiwerth (Croatia)
R. Vrhovac (Croatia)
K. Williams (USA)
D. Wolff (Germany)
R. Zeiser (Germany)



PARTICIPANTS Registration fee
5th International Chronic GvHD Symposium virtual delegate € 200,00
Fellow in Training (1), Student (2), Allied Health Professional (3) € 100,00
Undergraduate students free of charge
Retired doctors free of charge

VAT is included

Regular registration fee, registration fee for the members of the Societies, registration fee for other health professionals, registration fee for nurses and technicians, includes:

admission to all congress sessions by connecting to the online web platform of the Congress

  • pdf document with the booklet Final program
  • pdf document with Certificate of Atendance, and points of professional chambers

Note: Along with the application for participation, students should send a confirmation letter to the e-mail: vid.benko@btravel.pro confirming their status. The letter must be written on the faculty memorandum and addressed to the Congress agency BTravel Ltd.


All refund requests must be submitted in writing to the Congress agency BTravel and must be postmarked by March 15, 2021. Reimbursement of the fee less an administrative charge of 20 % and VAT will be refunded after the Congress. Cancellations received after March 15, 2021 will not be refunded.


REGISTRATION FEE (please choose):

5th International Chronic GvHD Symposium virtual delegate (200,00 €)Fellow in Training / Student / Allied Health Professional (100,00€)Undergraduate student / Retired doctors (FREE OF CHARGE)

PAYMENT (please choose):

Pay via credit card (VISA, MasterCard) - you will receive link for on-line paymentPay via bank transfer (you will receive a confirmation e-mail with payment details)


After you have complited the registration form, you will receive an e-mail with confirmation of your application.This confirmation is not a payment confirmation. You will
receive an offer for payment from the congress agency. After the payment, the preinvoice will be sent to the payer's e-mail.

Bank payment procedure: After receiving your completed registration form, we will send you an offer to make your payment.

Be sure to fill in all fields marked with an asterisk.


By registering for the congress, I give my permission to BTravel Ltd. to contact me about the congress, as well as all other similar meetings related to the medical profession. You will be able to contact BTravel Ltd. and withdraw this permission at any time.


Terms of cancellation:

All refund requests must be submitted in writing to the Congress agency BTravel and must be postmarked by March 15, 2021. Reimbursement of the fee less an administrative charge of 20 % and VAT will be refunded after the Congress. Cancellations received after March 15, 2021 will not be refunded.

ABSTRACTS</font size></font color>


Herby we invite fellows/people in training who would like to present an oral presentation in the PART II: cGvHD Progress Review to submit an abstract for consideration by the Scientific Committee. Presentations might be regarding papers on cGvHD published since 2018 that they are authors/co-authors and also regarding new work on cGvHD topic.

The abstracts should be submitted in English. The Scientific Committee will determine whether the abstract will be accepted for an oral presentation. The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission to the Congress agency, and of all communications thereafter.


In case co-authors are from different institutions, please enter a number after co-author's first name initial that matches the number of the institution. Example: Co-authors: 1 Smith J, 2 Tomic L

Institution: 1 Clinical Hospital Center Zagreb, Zagreb, Croatia, 2 General Hospital Zadar, Zadar, Croatia

Instructions for Writing Abstracts

- abstract should be written in English
- abstract length: up to 250 words
- the last name and first name of the author to be capitalized
- the first letter of the last name and the initial of the co-author’s name should be written in capital letters
- author's and co-author's last name and first name without titles
- author's and co-author's name of institution, city and country
- author's e-mail address
- 5 keywords
- text of the abstract: aim of the study, methods, results, and conclusion
- original abstracts will not be edited - linguistic accuracy is the responsibility of the author

The submission deadline: Monday, 1 March 2021, 12:00 noon CET. There will be no extension.
Notification of Acceptance/Rejection: Monday, 15 March 2021
Final oral presentation pre-recording deadline: Saturday, 6 April 2021



Technical organization information

Applications for participation, payment of registration fees, information for sponsors, technical organization:

Congress agency

BTravel Ltd.
Maksimirska cesta 112a, HR-10000 Zagreb, Croatia
Contact person: Vid Benko
M: +385 98 508 502
@: vid.benko@btravel.pro